Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 15 h ago

Avalo Therapeutics, Inc.: Point72 Asset Management, L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Point72 Asset Management amended its Schedule 13G filing covering its stake in Avalo Therapeutics, disclosing the change to the SEC under accession number 0000919574-26-008106. The filing is a passive-investor update rather than an activist position, and the headline gave no specific share count or percentage change. Schedule 13G amendments are typically triggered when a holder's ownership crosses or moves past the 5% threshold or when previously reported figures need correcting. The update matters because it shows Point72's continued exposure to the clinical-stage biotech, whose share price is sensitive to pipeline news and financing needs. Investors will watch for the amended filing's exact ownership figures and any subsequent 13F or Form 4 disclosures for a clearer read on Point72's position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Point72 Asset Management, L.P., Avalo Therapeutics, Inc.